Momenta Pharmaceuticals Inc.
) reported third quarter 2013 net loss per share of 50 cents,
wider than the Zacks Consensus Estimate of a loss of 48 cents.
The year-ago loss was 51 cents.
Third quarter revenues of $10.8 million were up 111.8 % year
over year. Revenues surpassed the Zacks Consensus Estimate of $10
million. Revenues comprised entirely of collaboration revenues in
the third quarter. Collaboration revenues included product
revenues and research and development revenues. Product revenues
represented royalty received from
pertaining to sales of the generic version of Lovenox. Product
revenues were $4.8 million, above the year-ago revenues of $2.6
million, due to adjustments to reserve accruals in the year-ago
quarter due to pricing pressures.
Research and development expenses were $27.4 million, up from
$20.2 million in the year-ago quarter. The increase was
attributable to process development, manufacturing and research
costs pertaining to the company's biosimilars program. General
and administrative expenses declined to $9 million from $11
million in the year-ago quarter mainly due to lower legal
2013 Guidance Maintained
Total operating expenses, excluding stock-based compensation
and net of collaborative revenue, are still expected to be around
$30 million per quarter in 2013. Momenta expects average net cash
usage in the range of $20 million to $24 million per quarter for
a total operating cash usage of roughly $80 million to $90
Apart from reporting third quarter earnings, Momenta provided
an update on its pipeline. In Jul 2013, Momenta received a
favorable ruling from the U.S. Court of Appeals for the Federal
Circuit which allows the company to launch its generic version of
Teva Pharmaceutical Industries Ltd.
) Copaxone after May 2014 subject to the U.S. Food and Drug
Administration (FDA) approval. Teva had filed a petition for a
rehearing of the Federal Circuit's opinion in the reported
quarter, which was later denied. Momenta's generic version of
Copaxone is currently under FDA review.
Three biosimilar candiates are currently under development,
namely, M923 and M834 for autoimmune and other inflammatory
indications, and M511 for the treatment of cancer. Momenta
intends to submit an Investigational New Drug (IND) application
for M923 in the second half of 2014.
A proof-of-concept phase 1/2 study evaluating M402 in
combination with Abraxane and Gemzar in patients with pancreatic
cancer is in progress. Data from Part A of the study will be out
in the first half of 2014.
Momenta carries a Zacks Rank #3 (Hold). Right now,
) looks more attractive with a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
MOMENTA PHARMA (MNTA): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.